Serum levels of soluble interleukin-2 receptor in association with oxidative stress index in patients with different types of HPV by Nayki, Cenk et al.
355
ORIGINAL PAPER /  GYNECOLOGY
Ginekologia Polska
2017, vol. 88, no. 7, 355–359
Copyright © 2017 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.a2017.0067
Serum levels of soluble interleukin-2 receptor  
in association with oxidative stress index in patients 
with different types of HPV
Cenk Nayki1, Murat Gunay2, Mehmet Kulhan1, Umit Nayki1,  
Murat Cankaya3, Nur Gozde Kulhan4
1Erzincan University, Medical Faculty, Department of Obstetrics and Gynecology, Erzincan, Turkey 
2Erzincan Univeristy, Medical Faculty, Department of Biochemistry, Erzincan, Turkey 
3Erzincan University, Science and Art Faculty, Department of Biology, Erzincan, Turkey 
4Mengucek Gazi Training and Research Hospital, Department of Obstetrics and Gynecology, Erzincan, Turkey
ABSTRACT
Objectives: The aim of this paper is to determine the oxidative–antioxidative status and levels of soluble interleukin-2 recep-
tor (sIL-2R) in serum of patients with different types of HPV infections and to compare it with patients who are negative for HPV.
Material and methods: A total of 80 women were divided into three groups as follows: Group 1 consisted of 25 women 
who were positive for HPV types 16 or 18; Group 2 consisted of 25 women who were positive for other types of HPV includ-
ing type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68; Group 3 consisted of 30 patients who were negative for HPV as a control 
group. Serum sIL-2R and plasma oxidative stress index (OSI) were analyzed.
Results: Serum sIL-2R levels were significantly higher in group 1 compared to group 2 and 3. OSI was found significantly 
increased in groups 1 and 2 compared to group 3. Also, we found a weak positive correlation between IL-2R and OSI.
Conclusion: sIL-2R and oxidative stress may have a role in HPV infection, especially in case of high-risk types.
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Human papillomavirus (HPV) is commonly observed 
in sexually active individuals. HPV infection can be asymp-
tomatic, can induce genital warts, or can result in cervical 
precancerous changes leading to cancer [1]. It is clinically 
important because of its relationship with cervical cancer. 
HPV can be clinically classified as “low-risk” and “high-risk” 
depending on the relative propensity of the HPV-associated 
lesions to undergo malignant progression. HPV 16 is the 
most prevalent high-risk HPV type, followed by HPV 18 and 
others [2]. High-risk HPV types are associated with precan-
cerous lesions such as cervical dysplasia or cervical squa-
mous intraepithelial lesions (SIL) leading to cervical cancer. 
However, not all infections with low-risk or high-risk types 
of HPV usually result in cervical disease [3]. The majority of 
HPV infections is subclinical and transient (80%) and in most 
of the cases they resolve spontaneously through effective 
immune response that eliminates virus or suppresses it to 
low undetectable levels [4].
In fact, neoplastic growth is an inappropriate outcome 
in the natural history of HPV, and a number of other events 
have to concur to induce the transformation of viral infection 
into a neoplastic lesion. Hence, a number of viral, host and 
environmental co-factors have been proposed as potential 
candidates [5]. Among them, oxidative stress and dysfunc-
tional immune response are of particular interest to us. 
Oxidative stress is a condition arising from an increased 
production of reactive oxygen species (ROS) associated 
with a decreased antioxidant capability of the cell. ROS are 
constantly generated in aerobic cells during normal physio- 
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logical processes, as well as during a number of processes 
including infections and inflammation [6]. 
Studies suggest that a host immune response to HPV is 
critical for effective control of HPV infection [7, 8]. It has been 
postulated that the cellular immune response, as opposed 
to the humoral response, plays a critical role in eliminating 
HPV [8]. 
Cytokines are pleiotropic glycoproteins that regulate 
biological activities such as cell survival, proliferation, dif-
ferentiation and activation, at both local and systemic levels. 
During inflammation, their excessive release may lead to 
both chronicity and pathogenicity. In this context, increased 
levels of sIL-2R are known to be a proxy for general im-
mune activation. It is expressed in various cell populations 
including activated Th1 and Th2 cells [9]. Levels of sIL-2R 
can be measured easily because a part of it is proteolytically 
cleaved and is found in serum [10]. Previous studies have 
demonstrated elevated serum levels of sIL-2R in various au-
toimmune disorders such as rheumatoid arthritis, systemic 
lupus erythematosus or Kawasaki disease, among transplant 
recipients who subsequently reject their graft, and in indi-
viduals with viral infections, including HIV and hepatitis, or 
hematological and lung tumors, as well as precancer and 
cancer of the uterine cervix [11–18].
Based on the data about the ability of a woman to re-
spond to HPV infection and to produce cytokines that pref-
erentially activate cell-mediated responses in association 
with oxidative stress, measurement of a specific cytokine 
would be a useful marker of adequate immune response 
to HPV. Thus, in the present study, we aim to determine the 
oxidative–antioxidative status and levels of sIL-2R in serum 
of patients with different types of HPV, which we compare 
with controls who are negative for HPV.
MATERIAL AND METHODS
This cross-sectional study consisted of 80 sexually active 
women who were admitted to the Gynecology Department 
of Erzincan University Mengucek Gazi Training and Research 
Hospital for a routine control. Subjects were questioned 
about socioeconomic, demographic, sexual, reproductive, 
medical and smoking history. Women were at age between 
30–45 and had regular menstrual cycles. A pelvic examina-
tion including visual inspection, bimanual and ultrasono-
graphic evaluation was performed to all patients. In addition 
to a cervical smear obtained with a cytobrush (ecto and 
endocervical), HPV DNA testing was conducted on speci-
men transport medium (STM) samples using the Hybrid 
Capture tube test (Digene Corp.) formatted to detect 13 HPV 
types (16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) [19]. 
Pap smears were classified according to the 2001 Bethesda 
system of reporting for cervical cytology [20]. All of the 
subjects were cytologically normal (Bethesda Class 1) with 
no concomitant other genital infection or history of pre-
cancerous cervical lesion and cervical cancer at the time of 
enrollment into the cohort. Other exclusion criteria applied 
were: smoking, use of any contraceptive medication, having 
multiple sexual partners, having any infection of genito- 
urinary system or anywhere else such as upper respiratory 
system within three months before the study and history 
of any malignancy. All of the patients positive for HPV were 
asymptomatic. Subjects were divided into three groups as 
follows: Group 1 consisted of 25 women who were positive 
for HPV types 16 or 18; Group 2 consisted of 25 women who 
were positive for the other types of HPV including types 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68; Group 3 consisted 
of 30 patients who were negative for HPV as control. The 
patients who were diagnosed as positive for HPV infection 
underwent colposcopic evaluation and upon unremarkable 
findings were enrolled into the study. The study was ap-
proved by the Ethics Committee of Erzincan University and 
a written informed consent was obtained from each patient. 
All procedures performed in this study were in accordance 
with ethical standards of institutional and/or national re-
search committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
A total of 10 mL of peripheral venous blood was taken 
for assessment of IL-2R, total oxidant status (TOS), total 
antioxidant capacity (TAC) and oxidative stress index (OSI). 
Within half an hour, the blood samples were centrifuged at 
3000 rpm and the serum was kept at –80°C until assayed.
sIL-2R levels were measured by chemiluminescent im-
munometric assay technique using a commercial kit (IL-2R 
for use on IMMULITE® 2000 systems, Siemens Healthcare, Dia- 
gnostics Products Ltd., UK). Result were presented as U/mL.
Plasma TOS was measured using a novel automated 
colorimetric measurement method developed by Erel [21]. 
According to this method, oxidants present in the sample 
oxidized the ferrous ion-o-dianisidine complex to a ferric 
ion. The oxidation reaction was enhanced by glycerol mo- 
lecules, which were abundant in the reaction medium. The 
ferric ion together with xylenol orange in an acidic medium 
gives a colored complex. The color intensity measured spec-
trophotometrically is related to the total amount of oxidant 
molecules present in the sample. The assay was calibrated 
with hydrogen peroxide and the results were expressed in 
terms of micromolar hydrogen peroxide equivalent per liter 
(μmol H2O2 Eq/L). 
TAC of plasma was measured using a novel automated 
colorimetric measurement method developed by Erel [22]. 
This method involves the production of the most potent bio-
logical radical — the hydroxyl radical with Fenton reaction 
to interact with a colorless substrate being O-dianisidine to 
produce the dianisyl radical, which is bright yellowish-brown 
in color. Upon the addition of a plasma sample, the oxida-
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tive reactions initiated by the hydroxyl radicals are being 
suppressed by the antioxidant components of the plasma, 
preventing the color change and thereby providing an effec-
tive measurement of TAC. The assay results were expressed 
as mmol Trolox Eq/L.
The ratio of TOS to TAC is accepted as the oxidative stress 
index (OSI), and the OSI value was calculated according to 
the following formula [23]:
OSI (arbitrary unit) = TOS (μmol H2O2 Eq/L) / TAC (mmol 
Trolox Eq/L).
The statistical analysis was performed using the Statis-
tical Package for the Social Sciences version 22 (SPSS Inc., 
Chicago, IL, USA). Results were expressed as mean ± stand-
ard error (SE). ANOVA and Kruskal-Wallis tests were used 
to analyze the differences among groups. The correlation 
between IL-2R and OSI were analyzed by Pearson correlation 
test. Statistical significance was set at p < 0.05.
RESULTS
Some demographic and reproductive characteristics are 
presented in Table 1. The differences between groups for 
age, gravidity, parity, number of abortions, age at menarche 
and age at first coitus were not statistically significant. 
Serum sIL-2R levels were significantly higher in group 
1 than in group 2 and 3 (p < 0.001). There was no statistically 
significant difference among groups for plasma TAC. How-
ever, TOS and OSI were found to be significantly increased in 
group 1 and 2 compared to group 3 (p = 0.013 and p = 0.001, 
respectively) (Table 2). Additionally, we found a weak posi-
tive correlation between IL-2R and OSI (r = 0.326, p < 0.003) 
(Figure 1).
DISCUSSION
Persistent infection of the cervix with a high risk HPV 
in association with co-factors required for the malignancy 
progression, leads to cervical cancer. Oxidative stress is 
one of the co-factors receiving great interest for its role 
during the progression of neoplasia. Oxidative status has 
been reported altered in blood of patients with cervical 
intraepithelial neoplasia (CIN). Studies on serum of patients 







Age (year)* 37.04 ± 4.6 36.72 ± 4.5 36.90 ± 4.3
Gravidity** 2 3 3
Parity** 2 2 2
Abortus* 0 0 0
Age at menarche (year)* 12.00 ± 0.9 12.24 ± 0.9 12.33 ± 0.8
Age at first coitus* 22.36 ± 2.8 22.88 ± 3.1 22.03 ± 4.5
*Data is presented as mean ± SE (standard error) 
**Data is presented as median
Table 2. Evaluation of IL2R, TOS, TAC and OSI in patients
Patients with HPV types 16,18
(n = 25)
Patients with other types of HPV
(n = 25)
Patients negative for HPV
(n = 30) P
sIL-2R [U/mL]* 391.3 ± 306.6 353.8 ± 191.8 282.3 ± 246.5 < 0.001
TOS [μmol H2O Eq/L]** 137.2 ± 55.4 61.5 ± 17.2 4.1 ± 0.6 0.013
TAC [mmol Trolox Eq/L]** 1.05 ± 0.06 1.15 ± 0.065 1.148 ± 0.12 0.718
OSI** 120.4 ± 37.9 48.7 ± 12.9 3.9 ± 0.5 0.001
*Data is presented as median ± interquartile range 











Figure 1. The weak positive correlation between sIL-2R and OSI, 
considering the HPV status of the patients
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with CIN and carcinoma of the cervix showed alterations in 
lipid peroxidation and impairment of antioxidant systems, 
either enzymatic or not [24, 25]. Additionally, other blood 
indicators of oxidative stress such as TBARS, ALA-D reactiva-
tion index, and vitamin C content were reported altered (in-
creased or decreased) in both low-grade and high-grade SIL, 
as well as cervical cancer [26]. In the present study, we found 
serum TOS and OSI to be significantly increased in patients 
with HPV type 16 and 18 compared to patients with other 
types of HPV and to patients who were negative for HPV. 
Our results are consistent with the literature in some parts.
There are numerous studies on cytokines and markers 
of immune response to HPV infection in the literature. Many 
of the authors have evaluated immune markers that were 
locally secreted in the cervix, tissue-based immune markers 
or immune response by patient-derived peripheral blood 
mononuclear cells (PBMCs) [27–30]. However, data concern-
ing infection-related immune response in either plasma or 
serum is limited. 
Previous studies have suggested that sIL-2R levels offer 
a rapid, reliable and noninvasive measure of disease activity, 
response to therapy and, in some cases, prognosis in a broad 
spectrum of conditions associated with T- or B-cell immune 
activation [11]. Similarly, sIL-2R levels have been evaluated in 
gynecologic conditions such as endometriosis, cervical cancer 
in association with HPV and in other genital cancers [31–33]. 
For example, Koumantakis et al. reported that serum sIL-2R 
levels, as well as IL-6 and IL-1a levels, were higher in women 
with endometriosis [33]. In another study, changes in serum 
sIL-2R levels were found to be correlated with ovarian cancer 
and it was suggested that serial sIL-2R measurement may 
be used in monitoring the disease course in patients with 
ovarian cancer [34]. On the other hand, Ferdeghini et al. no-
ticed that sIL-2R in serum was the most sensitive antigen for 
endometrial cancer, thus it could be used as a tumor marker 
for the management of these patients [32].
In this study, we have found serum levels of IL2R to be 
significantly increased in patients with HPV type 16 and 
18. In fact, Hildesheim et al. were the first to use plasma to 
evaluate immunity in HPV infection. However, their compari-
son of carcinogenic HPV-positive women with low-grade le-
sions to carcinogenic HPV-negative women with low-grade 
lesions failed to find a statistical difference in sIL-2R [35]. 
In contrast, Bais et al. measured numerous cytokines such 
as IL-2, IL-4, IL-10, IL-12, IFN-γ and TNF-α in plasma and 
reported that high-risk HPV infection was associated with 
higher mean plasma IL-2 levels [36]. Moreover, the results 
of the study by Gupta et al. revealed that serum IL-2 and 
sIL-2R levels were significantly higher in patients diagnosed 
with cervical intraepithelial neoplasm or invasive cervical can-
cer and indicated a host-vested cellular impairment in wom-
en with precancerous or cancerous lesions of the cervix [31]. 
Although results of Pardo-Govea et al. were consistent with 
such findings, they stated that type Th1 immune response 
prevails in patients with cervical precancerous lesions, 
whether HPV positive or not [37]. On the other hand, a dif-
ferent study suggested that sIL-2R levels are most likely 
a marker of response to the events of infection and can-
cerous invasion rather than a marker of a host immune 
response that predicts the risk of progression from LSIL to 
HSIL [10].
The present study has several limitations. First of all, this 
is a cross-sectional study with a small sample size. We have 
evaluated the serum levels of sIL-2R only while analyzing it 
in both serum and cervical tissue might lead to more stable 
results. Also, we did not evaluate serum sIL-2R levels by in-
dividual HPV type. Since the immune response may vary by 
HPV type, the levels should be considered individually [38]. 
On the other hand, we did not consider several factors re-
lated to HPV persistence and clearance that are documented 
in the literature and include menopausal status, smoking, 
oral contraceptive use or concomitant sexually transmitted 
disease, all of which may confound the results. In contrast 
to other studies, we kept cervical precancer and cancer 
patients out of the study population. We considered only 
patients with HPV infection that was limited to cervix. Also, 
we evaluated immunity in association with oxidative–anti-
oxidative status. In this regard, we found a weak correlation 
between sIL-2R and OSI. 
In conclusion, the measurements of serum or plasma 
cytokines, soluble immune markers and indicators of oxi-
dative–antioxidative status have been the center of atten-
tion in recent years with the hope it would provide useful 
diagnostic and prognostic information, and also insight to 
the pathogenesis of numerous diseases. In this regard, our 
results point to a possible role of sIL-2R and oxidative stress 
in HPV infection and also may provide an insight into the 
clinical usefulness of both sIL2R and OSI in patients infected 
with high-risk types of HPV. However, larger prospective 
studies are needed to reach for more accurate results and 
for more conclusions.
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